Physician profile
David Paul Smith
NPI 1003966961
$2,497.48
in general payments reported to CMS, 2019-2025
22 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $345 · 2021: $494 · 2022: $212 · 2023: $274 · 2024: $591 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $921.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $266.43 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $245.66 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $213.73 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $182.76 | 2019-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.92 | 2020-2025 | Jardiance |
| Amgen INC. | $111.86 | 2024-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.26 | 2024-2025 | Caplyta |
| Medtronic, INC. | $50.76 | 2024 | Kyphon Express II Kyphopak Tray |
| Abbott Laboratories | $38.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.84 | 2022 | |
| Merck Sharp & Dohme LLC | $32.58 | 2019-2020 | |
| Eisai INC. | $29.44 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $27.91 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.40 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $18.53 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $15.26 | 2022 | |
| Currax Pharmaceuticals LLC | $14.40 | 2022 | |
| Shire North American Group INC | $13.82 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.45 | 2022 | |
| Amarin Pharma, INC. | $13.06 | 2020 | |
| Genentech USA, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.